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Purpose: Our recent report indicated that tumor suppressor gene (p53) mutations and protein aberrant expression were
detected in pterygium. Inactivation of p53 by Human papillomavirus (HPV) 16/18 E6 plays a crucial role in cervical
tumorigenesis. In this study, we further speculate that p53 inactivation may be linked with HPV infection in pterygium
pathogenesis. To investigate the involvement of HPV 16/18 E6 in p53 inactivation in pterygium, the association between
HPV 16 or HPV 18 infection, the HPV E6 oncoprotein, and p53 protein expression was analyzed in this study.
Methods: HPV 16/18 infection was detected by nested-polymerase chain reaction  (nested-PCR), the p53  mutation was 
detected by direct sequencing, and the p53 and the HPV 16/18 E6 proteins were studied using immunohistochemistry
on 129 pterygial specimens and 20 normal conjunctivas.
Results: The HPV 16/18 was detected in 24% of the pterygium tissues (31 of 129) but not in the normal conjunctiva, and
the HPV16/18 E6 oncoprotein was detected in 48.3% of HPV 16/18 DNA-positive pterygium tissues (15 of 31). In addition,
p53 protein negative expression in pterygium was correlated with HPV16/18 E6 oncoprotein expression but not with a p53
mutation.
Conclusions: HPV 16/18 E6 contributes to HPV-mediated pterygium pathogenesis as it is partly involved in p53
inactivation and is expressed in HPV DNA-positive pterygium.
Pterygium has long been considered to be a degenerative
disease. However, following the finding that the p53 protein
is abnormally expressed in the epithelium, pterygium is now
thought to be an ultraviolet (UV)-related, uncontrolled cell
proliferation that is similar to a tumor [1-7].
The integration of high-risk Human papillomavirus 16/18
(HPV 16/18) DNA into the host chromosome to express the
E6 protein plays a crucial role in HPV-induced cervical
carcinogenesis [8-10]. E6 has many functions that may
contribute to its oncogenic potential. The classical function of
E6, which is relevant to cellular immortalization, is binding
to the tumor suppressor p53, thereby inducing p53
degradation [11]. The role of p53 is to safeguard the integrity
of the genome by inducing cell cycle arrest or apoptosis upon
DNA damage [12]. As a transcription factor, p53 upregulates
target genes involved in coordinating these responses such as
p21WAF1/CIP1, a cyclin-dependent kinase (CDK) inhibitor that
acts on cyclin E/cdk2 complexes, and murine double minute
(mdm2) [13,14]. Therefore, p53 inactivation by E6 leads to
chromosomal instability and increases the probability of an
HPV-infected cell evolving toward malignancy [11].
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Several reports revealed that low or no frequency of HPV
infection was found in pterygium [15-24] while some data
from Italy, Greece, the United Kingdom, and Brazil showed
that significantly higher frequencies of HPV infection (24%–
58.3%) were determined in pterygium than in conjunctivas
[18,20,24]. The association between HPV infection and
pterygium was then reasonably suggested to be geography-
and race-dependent. In our preliminary studies, the low
frequencies of p53 mutation and p53 positive immunostaining
were detected in pterygium [25]. This phenomenon is quite
similar to the pattern of p53 alteration found in cervical cancer
[26]. Therefore, we hypothesize that high-risk HPV 16/18
infection may be involved in pterygium pathogenesis in
Taiwan.
In this report, we analyzed p53 protein expression and
gene mutation in pterygium in comparison with HPV 16/18
infection and E6 oncoprotein expression in pterygium tissues
to understand whether the HPV infection was involved in
pterygium pathogenesis.
METHODS
Patients and controls: Pterygial samples were harvested from
129 patients who were undergoing pterygium surgery and
submitted a written informed consent approved by the
Institutional Review Board. Patients in whom the apex of the
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pterygium had invaded the cornea by more than 1 mm were
included in this study. Normal conjunctival samples were
collected from the superior conjunctivas of 10 patients
without pterygium and the medial conjunctivas of another 10
patients without pterygium and pinguecula, all of them were
undergoing cataract or vitreoretinal surgery, and these normal
samples were included as controls. All specimens were fixed
in formalin and were paraffin-embedded.
Nested polymerase chain reaction: Genomic DNA was
prepared from a tissue section and isolated by conventional
phenol-chloroform extraction, ethanol precipitation, and
finally dissolved in 20 μl of sterile distilled water. HPV viral
DNA was first amplified with type consensus primers, MY09
and MY11 [27], followed by a second round of amplification
with type specific primers flanking the L1 region to identify
the subtype (sequences of MY09: 5′-GCM CAG GGW CAT
AAY AAT GG-3′ and MY11: CGT CCM ARR GGA WAC
TGA TC; Type 16 primers: 5′-TAC TAA CTT TAA GGA
GTA CC-3′ and 5′-GTG TAT GTT TTT GAC AAG CAA
TT-3′; sequences of Type 18 primers: 5′-CCA AAT TTA
AGC AGT ATA GC-3′ and 5′-TTG TAC AAA ACG ATA
TGT ATC CA-3'). The final polymerase chain reaction (PCR)
product (10 μl) was loaded onto a 2% agarose gel, stained with
ethidium bromide, and visualized under UV illumination.
Appropriate negative and positive controls were included in
each PCR reaction. A part of β-actin in all samples was
amplified to exclude false-negative results while DNA
preparations from SiHa cells (containing HPV 16) and HeLa
cells (containing HPV 18) were used as positive controls.
Immunohistochemistry: All sections were deparaffinized in
xylene, sequentially rehydrated in alcohol, and washed in
phosphate-buffered saline. Sections used for p53 and HPV
16/18 E6 detection were heated in a microwave oven twice
for 5 min in citrate buffer (pH 6.0). Mouse anti-p53
monoclonal antibody (at a dilution of 1:200; DAKO,
Copenhagen, Denmark) and goat anti-HPV 16/18 E6 antibody
(at a dilution of 1:50; Santa Cruz Biotechnology, Santa Cruz,
CA) were used as the primary antibodies. The detail protocols
were described in our previous reports [28-30]. Negative
controls that did not include the primary antibodies were set
up. The cutoff value for immunohistochemical analysis was
set at 10%, which means the positive cutoff is when more than
10% of the cells are stained. The results were evaluated
independently by three observers and scored for the
percentage of positive or negative.
p53 mutation analysis: Mutations in exons 4, 5, 6, 7, and 8 of
p53 were determined by direct sequencing, and the methods
were described in our previous report [25]. DNA was
extracted from the paraffin-embedded pterygium tissues by
traditional proteinase K digestion and phenol-chloroform
extraction. Target sequences were amplified in a 50 μl reaction
mixture containing 20 pmol of each specific primer, 2.5 units
of Taq polymerase (Takara Shuzo, Shiga, Japan), 0.5 mM
dNTPs, 5 μl of PCR reaction buffer, and 1 μl of genomic DNA
as the template. β-actin was used as an internal control. An
initial cycle was performed for 5 min at 94 °C, and then 35
cycles each for 40 s at 94 °C, 40 s at 54 °C, and 1 min at 72 °C.
PCR products were then purified with the QIAEX Gel
Extraction Kit (Qiagen, Germantown, MD). Approximately
20 ng of purified PCR product (QIAquick PCR Purification
kit; Qiagen) was directly sequenced using the Big Dye
Terminator Reaction kit, version 3.1 (Applied Biosystems,
Foster City, CA) and sequenced by an auto-sequencing system
(Applied Biosystems 3100 Avant Genetic Analyzer; Applied
Biosystems). All of the p53 mutations were confirmed by
direct sequencing of both strands.
Statistical analysis: Statistical analysis was performed using
the SPSS statistical software program (SPSS Inc., Chicago,
IL). Fisher’s exact test was applied for statistical analysis. A
p value less than 0.05 was considered to be statistically
significant.
RESULTS
There were 76 males and 53 females in the pterygium group
(age range=50–83 years, mean=64.7 years), and 10 males and
10 females in the control group (age range=55–75 years,
mean=67.2 years).
HPV 16/18 DNA detected in pterygium but not in control
group: To elucidate the association between HPV infection
and pterygium development, nested PCR with two different
sets of primers was used to examine the existence of HPV
16/18 DNA in pterygium tissues and the control group. As
shown in Table 1, the detection frequency of HPV 16/18 DNA
in pterygium (31 of 129, 24%) was higher than that of control
patients (0 of 20, 0%; p=0.014). When the study subjects were
stratified by gender and age, HPV 16/18 DNA detection
frequency was not different. The higher prevalence of HPV
TABLE 1. THE DIFFERENCES OF HPV 16/18 INFECTION  BETWEEN PTERYGIUM TISSUES AND CONJUNCTIVA CONTROL.
Parameters Patients (%) Control (%) p value
HPV 16/18 DNA
Negative 98 (76.0%) 20 (100%)
Positive 31 (24.0%) 0 (0%) 0.014
HPV 16/18 DNA was detected by nested-PCR.
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16/18 in pterygium suggests that HPV infection may play a
role in pterygium pathogenesis.
HPV 16/18 E6 protein were detected in HPV-positive
pterygium tissues: After successfully detecting HPV infection
in pterygium tissues, we attempted to determine by
immunohistochemistry whether HPV 16/18 E6 is expressed
to verify the association between HPV infection and
HPV16/18 E6 expression. HPV 16/18 E6 protein staining was
limited to the nuclei of the epithelial layer (Figure 1). Our data
showed that HPV 16/18 E6 was only detected in 48.3% (15
Figure 1. Representative positive and negative immunostaining for
HPV 16/18 E6 protein in paraffin sections of pterygium.
Representative positive HPV 16/18 E6 immunostaining is shown in
(A). The brown color pointed out by the red arrow indicates a HPV
16/18 positive signal. Negative HPV 16/18 E6 immunostaining is
shown in (B).
of 31) of HPV 16/18 DNA positive pterygium tissues. Not any
HPV-negative pterygium and control group had HPV 16/18
E6 protein expression (Table 2; p<0.0001).
p53 inactivation associated with HPV 16/18 E6 protein
expression: Immunohistochemistry was used to detect the
HPV 16/18 E6 oncoprotein and p53 expressions (Figure 2) in
the 129 pterygium tissues and to elucidate whether HPV 16/18
E6 affects p53 protein expression. In addition, p53 mutations
were also analyzed by direct sequencing to verify the
correlation with p53 protein expression. As shown in Table 3,
the frequency of p53 negative expression was higher than
positive expression (12 of 15, 80.0% versus 3 of 15, 20.0%,
respectively) in 15 HPV 16/18 E6 positive patients. Of these
three HPV+/p53+ patients, two had a p53 mutation. The site
of the p53 mutation for patient 5 was at exon 4, codon 107,
and for patient 6, it was at exon 7, codon 234. Additionally,
p53 mutations were detected in 9.3% (12 of 129) of the
pterygium group but not detected in the control group. No
correlation was observed between p53 protein expression and
its gene mutation. This result was concordant with our
previous report [25].
DISCUSSION
High-risk HPV E6 has many functions that may contribute to
its oncogenic potential. The classical function of E6, which is
relevant to cellular immortalization, is the binding to the
tumor suppressor, p53, thereby inducing p53 degradation
[11].The integration of high-risk HPV16/18 DNA into the
host chromosome to express the E6 protein plays a crucial role
in HPV-induced cervical carcinogenesis [8-10]. Throughout
literature, the prevalence of HPV infection in pterygia varies
from 0%−54% [15-24]. All of these reports detected HPV
infection at a DNA level but not the HPV E6 oncoprotein. As
far as we know, this is the first study to report that the HPV
16/18 E6 oncoprotein was detected in pterygia tissues. In this
study, the HPV 16/18 E6 protein was detected in 11.6% (15
of 129) of the pterygium patients, but the HPV 16/18 DNA
detection rate was 24.0% (31 of 129). E6 oncoprotein
expression was detected in only 48.4% of the HPV-positive
pterygia cells. In previous studies, high-risk HPV E6 gene
expression has been evaluated by reverse transcription
polymerase chain reaction (RT–PCR), RNA in situ
hybridization, and immunohistochemistry [31-37]. Although
RT–PCR is more sensitive in the detection of HPV E6 than
immunohistochemistry, results from the RT–PCR detection
of HPV E6 may be misleading due to contamination of other
TABLE 2. RELATIONSHIP OF HPV 16/18 INFECTION AND E6 ONCOPROTEIN EXPRESSION IN PTERYGIA TISSUES.
HPV 16/18 DNA p valueNegative Positive
Negative 98 0
Positive 16 15 <0.0001
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HPV 16/18 E6 oncoprotein
Figure 2. Representative positive and negative immunostainings for
p53 protein in paraffin sections of pterygium. Representative positive
p53 immunostaining is shown in (A), negative p53 immunostaining
is shown in (B). The brown color pointed out by red arrow indicates
p53 positive signal.
cells. Therefore, in this study, we used the
immunohistochemistry data to provide direct evidence
showing that p53 inactivation in pterygium may be correlated
with HPV 16/18 E6 oncoprotein expression (Table 3).
Additionally, our data show that p53 expression was not
associated with a p53 mutation (Table 3), which is
inconsistent with a previous study [38] showing that positive
p53 expression was due to the increased protein stability by
p53 missense mutations. In addition, E6 variants with
mutations in the NH2-terminal region lost the ability to bind
with E6-associated protein (E6AP) and failed to cause p53
protein degradation [39]. Therefore, the patients with both
HPV 16/18 E6 and p53 protein positive expressions may
correlate with also having a p53 mutation or the E6 variant.
Based on these results, we hypothesize that inactivation of p53
by a high-risk HPV E6 oncoprotein may play a role in a HPV-
mediated pterygium pathogenesis.
In conclusion, our study demonstrates for the first time
that high-risk HPV E6 oncoprotein is indeed expressed in
pterygium and is linked to p53 protein negative expression.
Moreover, p53 negative expressions were not correlated with
gene mutations. These data provide molecular evidence that
HPV 16/18 E6 contributes to HPV-mediated pterygium
pathogenesis as it is partly involved in p53 inactivation and is
expressed in HPV DNA-positive pterygium.
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1 + - Wild type
2 + - Wild type
3 + - Wild type
4 + - Wild type
5 + + C→G (exon 4, codon 107)
6 + + T→A (exon 7, codon 234)
7 + - Wild type
8 + - Wild type
9 + - Wild type
10 + - Wild type
11 + - Wild type
12 + - Wild type
13 + - Wild type
14 + + Wild type
15 + - Wild type
The p53 and HPV E6 proteins were detected by immunohistochemistry. The cutoff value of immunohistochemical analysis was
set at 10%, which means that those with more than 10% of their cells stained are considered to be positive. The p53 mutation
was detected by direct DNA sequence.
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TABLE 3. RELATIONSHIP OF HPV 16/18 E6 ONCOPROTEIN, P53 MUTATION, AND P53 PROTEIN EXPRESSION IN PTERYGIUM TISSUES.
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